{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:22:22Z","timestamp":1787595742453,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"vor","delay-in-days":288,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.lrr.2021.100275","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T15:12:40Z","timestamp":1635174760000},"page":"100275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Role of antibody-based therapy in indolent non-Hodgkin's lymphoma"],"prefix":"10.1016","volume":"16","author":[{"given":"Patrick","family":"Willard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Yazbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lrr.2021.100275_bib0001","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri1265","article-title":"Monoclonal antibodies: the story of a discovery that revolutionized science and medicine","volume":"4","author":"Alkan","year":"2004","journal-title":"Nat. Rev. Immunol"},{"issue":"1","key":"10.1016\/j.lrr.2021.100275_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci"},{"issue":"9","key":"10.1016\/j.lrr.2021.100275_bib0003","first-page":"3147","article-title":"Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen","volume":"40","author":"Nadler","year":"1980","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.lrr.2021.100275_bib0004","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/14656566.2019.1582643","article-title":"Choosing the right pharmacotherapy for non-Hodgkin's lymphoma: does one size fit all?","volume":"20","author":"Juhaishi","year":"2019","journal-title":"Expert Opin. Pharmacother"},{"key":"10.1016\/j.lrr.2021.100275_bib0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab\u2014the world's first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.lrr.2021.100275_bib0006","first-page":"486","article-title":"Long term follow-up of the PRIMA Study: half of patients receiving rituximab maintenance remain progression free at 10 years","volume":"130","author":"Salles","year":"2017","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.lrr.2021.100275_bib0007","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lrr.2021.100275_bib0008","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol"},{"issue":"10","key":"10.1016\/j.lrr.2021.100275_bib0009","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"14","key":"10.1016\/j.lrr.2021.100275_bib0010","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"Augment: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J. Clin. Oncol"},{"issue":"17","key":"10.1016\/j.lrr.2021.100275_bib0011","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J. Clin. Oncol"},{"issue":"5","key":"10.1016\/j.lrr.2021.100275_bib0012","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.15641","article-title":"Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA\/IELSG36 study","volume":"183","author":"Iannitto","year":"2018","journal-title":"Br. J. Haematol"},{"issue":"22","key":"10.1016\/j.lrr.2021.100275_bib0013","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the gadolin study","volume":"36","author":"Cheson","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol"},{"issue":"14","key":"10.1016\/j.lrr.2021.100275_bib0014","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"16","key":"10.1016\/j.lrr.2021.100275_bib0015","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1182\/bloodadvances.2020001942","article-title":"A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy","volume":"4","author":"Maloney","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.lrr.2021.100275_bib0016","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/bjh.17420","article-title":"A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A\u00a0+\u00a0B study)","volume":"193","author":"Rummel","year":"2021","journal-title":"Br. J. Haematol"},{"issue":"2","key":"10.1016\/j.lrr.2021.100275_bib0017","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjh.14534","article-title":"A phase 1\/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"Br. J. Haematol"},{"issue":"21","key":"10.1016\/j.lrr.2021.100275_bib0018","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.2019002118","article-title":"Ublituximab and umbralisib in relapsed\/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"134","author":"Lunning","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lrr.2021.100275_bib0019","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann. Oncol"},{"issue":"6","key":"10.1016\/j.lrr.2021.100275_bib0020","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12185-019-02635-9","article-title":"A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma","volume":"109","author":"Ohmachi","year":"2019","journal-title":"Int. J. Hematol"},{"issue":"10","key":"10.1016\/j.lrr.2021.100275_bib0021","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1586\/14737140.6.10.1341","article-title":"Epratuzumab in the therapy of oncological and immunological diseases","volume":"6","author":"Goldenberg","year":"2006","journal-title":"Expert Rev. Anticancer Ther"},{"issue":"16","key":"10.1016\/j.lrr.2021.100275_bib0022","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","article-title":"Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-hodgkin's lymphoma: phase I\/II clinical trial results","volume":"10","author":"Leonard","year":"2004","journal-title":"Clin. Cancer Res"},{"issue":"21","key":"10.1016\/j.lrr.2021.100275_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.28299","article-title":"A phase II trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701","volume":"119","author":"Grant","year":"2013","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.lrr.2021.100275_bib0024","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","article-title":"Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma","volume":"24","author":"Strauss","year":"2006","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol"},{"issue":"14","key":"10.1016\/j.lrr.2021.100275_bib0025","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.lrr.2021.100275_bib0026","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"10.1016\/j.lrr.2021.100275_bib0027","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1182\/blood-2019-124254","article-title":"Blinatumomab\/lenalidomide in relapsed\/refractory non-Hodgkin's lymphoma: a phase i california cancer consortium study of safety, efficacy and immune correlative analysis","volume":"134","author":"Poh","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2021.100275_bib0028","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-135839","article-title":"Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a phase I dose-escalation trial","volume":"136","author":"Assouline","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.lrr.2021.100275_bib0029","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.lrr.2021.100275_bib0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136659","article-title":"Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-hodgkin lymphoma, including patients refractory to car T therapy","volume":"136","author":"Bannerji","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2021.100275_bib0031","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-133820","article-title":"Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed\/refractory B-Cell non-hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: updated dose escalation data","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.lrr.2021.100275_bib0032","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2017-06-781989","article-title":"Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma","volume":"130","author":"Liu","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lrr.2021.100275_bib0033","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lrr.2021.100275_bib0034","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.lrr.2021.100275_bib0035","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1200\/JCO.2017.35.15_suppl.7519","article-title":"Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study","volume":"35","author":"Nastoupil","year":"2017","journal-title":"J. Clin. Oncol"},{"issue":"18","key":"10.1016\/j.lrr.2021.100275_bib0036","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.lrr.2021.100275_bib0037","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lrr.2021.100275_bib0038","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"19","key":"10.1016\/j.lrr.2021.100275_bib0039","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2021.100275_bib40","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-019-0687-5","article-title":"Marginal Zone Lymphoma: State-of-the-Art Treatment","author":"Sindel","year":"2019","journal-title":"Curr Treat Options Oncol."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221304892100042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221304892100042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:08:15Z","timestamp":1761959295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221304892100042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":40,"alternative-id":["S221304892100042X"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2021.100275","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of antibody-based therapy in indolent non-Hodgkin's lymphoma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2021.100275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100275"}}